Vistagen Pops 677% on Social Anxiety Spray Trial Success

Vistagen Pops 677% on Social Anxiety Spray Trial Success

Source: 
Yahoo/Bloomberg
snippet: 

 A beaten down micro-cap biotech company, Vistagen Therapeutics Inc., notched its best day ever, surging by as many as four digits after its experimental nasal spray for social anxiety disorder hit targets in a late-stage trial.